Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q2 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
Highlights of the report include:
Approved gene, cell, and RNA therapies
Pipeline of gene,cell, and RNA therapies
Activity including deal-making, start-up financing, noteworthy events, and upcoming catalysts for gene, cell, and RNA therapies
Ly Specialises in
21+ years of experience
Connecticut , USA
Amanda Specialises in
22+ years of experience
Shardha Specialises in
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q1 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q4 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
This Q3 2021 report introduces two new gene therapies in the European (EU) and China, 323 gene therapies in preclinical development, and the on-going progress of gene therapies for rare diseases and non-oncology indications.
Important updates for the Q2 2021 report include the approval of a new gene therapy in Japan, the expansion of gene therapy approvals to three new countries, more than 1,300 gene and cell therapy candidates in development for oncology, and a significant increase for financing for start-ups!
We have received your request and we will get back to you soon.
